Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide

被引:51
|
作者
Esquirol, Albert [1 ]
Pascual, Maria Jesus [2 ]
Kwon, Mi [3 ]
Perez, Ariadna [4 ]
Parody, Rocio [5 ]
Ferra, Christelle [6 ]
Garcia Cadenas, Irene [1 ]
Herruzo, Beatriz [2 ]
Dorado, Nieves [3 ]
Hernani, Rafael [4 ]
Sanchez-Ortega, Isabel [5 ]
Torrent, Anna [6 ]
Sierra, Jorge [1 ]
Martino, Rodrigo [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, IIB St Pau & Jose Carreras Leukemia Res Inst, Hematol Dept, Barcelona, Spain
[2] Hosp Reg Univ, Hematol Dept, Malaga, Spain
[3] Hosp Gregorio Maranon, Hematol Dept, Madrid, Spain
[4] Hosp Clin Univ, Hematol Dept, Madrid, Spain
[5] Bellvitge Hosp, Hematol Dept, Barcelona, Spain
[6] Hosp Badalona Germans Trias & Pujol, Hematol Dept, Badalona, Spain
关键词
BONE-MARROW-TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; RISK-FACTORS; HEMATOLOGIC MALIGNANCIES; HEMORRHAGIC CYSTITIS; ACUTE-LEUKEMIA; BACTEREMIA; OUTCOMES; DONORS; ADULTS;
D O I
10.1038/s41409-021-01328-4
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Severe infections and their attributable mortality are major complications in recipients of allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult patients who received haploSCT with PTCy. The median follow-up for survivors was 37 months. The overall incidence of bloodstream infections by gram-positive and gram-negative bacteria at 37 months was 51% and 46%, respectively. The incidence of cytomegalovirus infection was 69%, while Epstein Barr virus infections occurred in 10% of patients and hemorrhagic cystitis in 35% of cases. Invasive fungal infections occurred in 11% at 17 months. The 3-year incidence of infection-related mortality was 19%. The median interval from transplant to IRM was 3 months (range 1-30), 53% of IRM occurred >100 days post-haploSCT. Risk factors for IRM included age >50 years, lymphoid malignancy, and developing grade III-IV acute GvHD. Bacterial infections were the most common causes of IRM (51%), mainly due to gram-negative bacilli BSI. In conclusion, severe infections are the most common causes of NRM after haploSCT with PTCy, with a reemergence of gram-negative bacilli as the most lethal pathogens. More studies focusing on the severe infections after haploSCT with PTCy and differences with other types of alloSCT in adults are clearly warranted.
引用
收藏
页码:2432 / 2444
页数:13
相关论文
共 50 条
  • [41] Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
    Samuel Cytryn
    Maher Abdul-Hay
    Clinical Hematology International, 2020, 2 (2) : 49 - 58
  • [42] Reduced Dose of Post-Transplant Cyclophosphamide for HLA Haploidentical Peripheral Blood Stem Cell Transplantation
    Morishige, Satoshi
    Yamasaki, Yoshitaka
    Oya, Shuki
    Nakamura, Takayuki
    Ymaguchi, Maki
    Aoyama, Kazutoshi
    Seki, Ritsuko
    Mouri, Fumihiko
    Osaki, Koichi
    Nagafuji, Koji
    BLOOD, 2018, 132
  • [43] Haploidentical Stem Cell Transplantation for Class 3 Thalassemia major using post-transplant Cyclophosphamide
    Khattab, Eman
    Najjar, Rula
    Tbakhi, Abdelghani
    Rihani, Rawad
    Abu Shanap, Mayada
    Hashem, Hasan
    Ahmod, Aram
    Hussein, Nilly
    Sultan, Iyad
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 442 - 443
  • [44] Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide
    Sarita Rani Jaiswal
    Aditi Chakrabarti
    Sumita Chatterjee
    Sneh Bhargava
    Kunal Ray
    Suparno Chakrabarti
    International Journal of Hematology, 2016, 103 : 234 - 242
  • [45] Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide
    Jaiswal, Sarita Rani
    Chakrabarti, Aditi
    Chatterjee, Sumita
    Bhargava, Sneh
    Ray, Kunal
    Chakrabarti, Suparno
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (02) : 234 - 242
  • [46] Haploidentical Stem Cell Transplantation With Post-transplant Cyclophosphamide for Pediatric Acute Leukemia is Safe and Effective
    Sharma, Anil
    Rastogi, Neha
    Chatterjee, Goutomi
    Kapoor, Rohit
    Nivargi, Sagar
    Yadav, Satya P.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (07) : E1033 - E1036
  • [47] Impact of Early Immune Reconstitution after Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide
    Dorado, Nieves
    Perez-Corral, Ana
    Kwon, Mi
    Solan, Laura
    Bailen, Rebeca
    Pascual, Cristina
    Serrano, David
    Anguita, Javier
    Balsalobre, Pascual
    Martinez-Laperche, Carolina
    Luis Diez-Martin, Jose
    BLOOD, 2018, 132
  • [48] ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WAS RELATED TO LESS INPATIENT COST COMPARED TO CORD BLOOD TRANSPLANTATION
    Kurita, N.
    Yokoyama, Y.
    Kato, T.
    Nishikii, H.
    Sakata-Yanagimoto, M.
    Obara, N.
    Hasegawa, Y.
    Chiba, S.
    HAEMATOLOGICA, 2017, 102 : 619 - 619
  • [49] Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide in the Chilean National Health System. a Single Center Study
    Puga, Barbara
    Benavente, Rafael
    Bass, Francisca
    Javiera Molina, M.
    Andrade, Alejandro
    Majlis, Alejandro
    Elena Cabrera, Maria
    Undurraga, Soledad
    BLOOD, 2023, 142
  • [50] The Results of Allogeneic Hematopoietic Stem Cell Transplantation from HLA-haploidentical Donor with post-transplant Cyclophosphamide Regimen in Children
    Burya, Alexandra
    Kirgizov, Kirill
    Nikolaeva, Yulia
    Konstantinova, Veronica
    Pristanskova, Ekaterina
    Sidorova, Natalia
    Mezenceva, Anastasia
    Olhova, Ludmila
    Blagonravova, Oxana
    Filina, Olga
    Petrova, Larisa
    Skorobogatova, Elena
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 308 - 309